LUZHU BIOTECH-B2480.HKValuation Analysis

As of Oct 16, 2026, LUZHU BIOTECH-B (2480.HK) trades at a negative P/E (-20.17x, due to a recent net loss), P/B of 4.48x, P/S of N/A, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 28th percentile over the trailing 10Y window (vs. 31st percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/B ranks at the 71st percentile within its industry and the 88th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/B percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. LUZHU BIOTECH-B operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.